search
Back to results

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Primary Purpose

Psychomotor Agitation

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
haloperidol+promethazine
haloperidol + midazolam
olanzapine
Ziprasidone
Sponsored by
University of Sao Paulo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychomotor Agitation focused on measuring Violence, Aggression, Psychiatric emergencies, Psychomotor agitation, Violent patient

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients featuring psychomotor agitation, with clinical need for intramuscular injection

Exclusion Criteria:

  • delirium, severe or unstable general medical condition, previous history of severe adverse effects with one of the treatment options

Sites / Locations

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto, USP

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

ziprasidone injection

haloperidol + midazolam, injection

haloperidol + promethazine, injection

olanzapine, injection

Arm Description

ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation

Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation

haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation

olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation

Outcomes

Primary Outcome Measures

Reduction in the agitation score
Agitation scores were evaluated through two previously validated specific scales: ACES ( Agitation Calmness Evaluating Scale) and PANSS-EC ( Positive and Negative Symptoms Scale- Excited Component). The measure was collected by a blind rater at baseline and the subsequent measures aimed to evaluate the drug effect over agitation scores.

Secondary Outcome Measures

Adverse effects
Aiming to evaluate the occurrence of adverse effects in the 24 hours period of observation after administrating the first injection (Baseline), an exert from the UKU scale (Ugvalg klinisk Undersgelser Side Effect Scale )was applied by a blind rater, to evaluate the presence and intensity of possible side effects.

Full Information

First Posted
November 28, 2011
Last Updated
December 1, 2011
Sponsor
University of Sao Paulo
search

1. Study Identification

Unique Protocol Identification Number
NCT01485692
Brief Title
Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation
Official Title
Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to evaluate the efficacy and safety of four options of medications in the management of acute psychomotor agitation,or violence and aggression situations in health services. All of the treatment options are already approved and currently used for this purpose. The options are: haloperidol plus midazolam, haloperidol plus promethazine, olanzapine and ziprasidone. The investigators hypothesized that all treatment options are effective in the treatment of acute agitation, but the combination haloperidol plus promethazine could elicit more adverse affects than the others.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychomotor Agitation
Keywords
Violence, Aggression, Psychiatric emergencies, Psychomotor agitation, Violent patient

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ziprasidone injection
Arm Type
Active Comparator
Arm Description
ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
Arm Title
haloperidol + midazolam, injection
Arm Type
Active Comparator
Arm Description
Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
Arm Title
haloperidol + promethazine, injection
Arm Type
Active Comparator
Arm Description
haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
Arm Title
olanzapine, injection
Arm Type
Active Comparator
Arm Description
olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
Intervention Type
Drug
Intervention Name(s)
haloperidol+promethazine
Intervention Description
haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
Intervention Type
Drug
Intervention Name(s)
haloperidol + midazolam
Intervention Description
haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
Intervention Type
Drug
Intervention Name(s)
olanzapine
Intervention Description
olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
Intervention Type
Drug
Intervention Name(s)
Ziprasidone
Intervention Description
ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
Primary Outcome Measure Information:
Title
Reduction in the agitation score
Description
Agitation scores were evaluated through two previously validated specific scales: ACES ( Agitation Calmness Evaluating Scale) and PANSS-EC ( Positive and Negative Symptoms Scale- Excited Component). The measure was collected by a blind rater at baseline and the subsequent measures aimed to evaluate the drug effect over agitation scores.
Time Frame
90 minutes
Secondary Outcome Measure Information:
Title
Adverse effects
Description
Aiming to evaluate the occurrence of adverse effects in the 24 hours period of observation after administrating the first injection (Baseline), an exert from the UKU scale (Ugvalg klinisk Undersgelser Side Effect Scale )was applied by a blind rater, to evaluate the presence and intensity of possible side effects.
Time Frame
12,24 hours after baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients featuring psychomotor agitation, with clinical need for intramuscular injection Exclusion Criteria: delirium, severe or unstable general medical condition, previous history of severe adverse effects with one of the treatment options
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Celia Mantovani, MD
Organizational Affiliation
University of Sao Paulo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto, USP
City
Ribeirão Preto
State/Province
São Paulo
ZIP/Postal Code
14048-900
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
23609398
Citation
Mantovani C, Labate CM, Sponholz A Jr, de Azevedo Marques JM, Guapo VG, de Simone Brito dos Santos ME, Pazin-Filho A, Del-Ben CM. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol. 2013 Jun;33(3):306-12. doi: 10.1097/JCP.0b013e3182900fd6.
Results Reference
derived

Learn more about this trial

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

We'll reach out to this number within 24 hrs